Page 71 - TD-4-2

Tumor Discovery Glioblastoma treating fields system

Looking ahead, future research should focus on doi: 10.3390/cancers15072116
optimizing electric field parameters, exploring combination 2. Saqib M, Zahoor A, Rahib A, et al. Clinical and translational
therapies, and integrating real-time monitoring for adaptive advances in primary brain tumor therapy with a focus on
treatment strategies. Clinical translation will require glioblastoma-A comprehensive review of the literature.
rigorous trials to validate the safety and effectiveness of this World Neurosurg X. 2024;24:100399.
technology in human patients. If successfully implemented, doi: 10.1016/j.wnsx.2024.100399
our TTF system could represent a significant advancement
in glioblastoma treatment, offering a non-invasive and 3. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-
highly adaptable therapeutic option for improving patient treating fields plus maintenance temozolomide vs
outcomes. Overall, this study contributes valuable insights maintenance temozolomide alone on survival in patients
into the engineering and biological aspects of TTF therapy, with glioblastoma: A randomized clinical trial. JAMA.
2017;318(23):2306-2316.
paving the way for further innovations in electric field-
based cancer treatments. doi: 10.1001/jama.2017.18718

Acknowledgments 4. Stupp R, Wong E, Kanner A, et al. NovoTTF-100A versus
physician’s choice chemotherapy in recurrent glioblastoma:
None. a randomised phase III trial of a novel treatment modality.
Eur J Cancer. 2012;48(14):2192-2202.
Funding doi: 10.1016/j.ejca.2012.04.011
This research was supported by National Natural Science 5. Wong E, Lok E, Swanson K. Clinical benefit in recurrent
Foundation of China (52302118), Fundamental Research glioblastoma from adjuvant NovoTTF-100A and TCCC
Funds for the Central Universities, Sun Yat-sen University after temozolomide and bevacizumab failure: A preliminary
(24qnpy312), and Zhejiang Provincial Natural Science observation. Cancer Med. 2015;4(3):383-391.
Foundation of China under Grant No. LQ23B050006.
doi: 10.1002/cam4.421
Conflict of interest 6. Kirson E, Dbalý V, Tovarys F, et al. Alternating electric fields
arrest cell proliferation in animal tumor models and human
The authors declare that they have no competing interests.
brain tumors. Proc Natl Acad Sci U S A. 2007;104(24):
Author contributions 10152-10157.
doi: 10.1073/pnas.0702916104
Conceptualization: Zhiyong Wang
Formal analysis: Han Lv 7. Warren K, Liu L, Liu Y, et al. The impact of timing of
Investigation: Xindong Wang concurrent chemoradiation in patients with high-grade
Methodology: Xindong Wang glioma in the era of the stupp protocol. Front Oncol.
Writing–original draft: Xindong Wang 2019;9:186.
Writing–review & editing: Han Lv, Xian Wang doi: 10.3389/fonc.2019.00186
8. Pless M, Weinberg U. Tumor treating fields: Concept,
Ethics approval and consent to participate evidence and future. Expert Opin Investig Drugs.
The study is approved by Ethics Review Committee of 2011;20(8):1099-1106.
Hangzhou Yanqu Information Technology Co., Ltd. doi: 10.1517/13543784.2011.583236
(approval no.: 202404A010).
9. Gutin P, Wong E. Noninvasive application of alternating
Consent for publication electric fields in glioblastoma: A fourth cancer treatment
modality. Am Soc Clin Oncol. 2012;32:126-131.
Not applicable.
doi: 10.14694/EdBook_AM.2012.32.122
Availability of data 10. Cao Q, Hajosch A, Kast R, et al. Tumor Treating Fields
All datasets on which the conclusions of this paper rely (TTFields) combined with the drug repurposing
approach CUSP9v3 induce metabolic reprogramming and
have been presented in the main manuscript.
synergistic anti-glioblastoma activity in vitro. Br J Cancer.
References 2024;130(8):1365-1376.
doi: 10.1038/s41416-024-02608-8
1. Yalamarty S, Filipczak N, Li, X, et al. Mechanisms of
resistance and current treatment options for glioblastoma 11. Rominiyi O, Vanderlinden A, Clenton S, et al. Tumour
multiforme (GBM). Cancers (Basel). 2023;15(7):2116. treating fields therapy for glioblastoma: Current advances

Volume 4 Issue 2 (2025) 63 doi: 10.36922/td.7171